Toa Eiyo Ltd.

Takeshi Hasegawa

Hidekazu Masaki

Atsuo Takahashi

Shin-ichi Kazayama

Fumiya Yoneyama

Hideki Yamada

Akira Tatsui

Shinji Takai

Mizuo Miyazaki

Yusuke Mizuno

Tetsuo Kuze

Takahiro Morita

Shoji Satoh

Shin-ya Ohnuma

Toshihiro Sawabe

Tomoyuki Sada

Akiyuki Takaya

Fumito Maruyama

Provided is a novel therapeutic agent for glaucoma, which has sGC-activating action. A therapeutic agent for glaucoma or an ocular hypotensive agent, which contains, as an effective component, a compound represented by Formula (I-a) or Formula (I-b) and having a Log D value of more than 1.5 and less than 2.5, or a pharmaceutically acceptable salt thereof. [In formulae (I-a) and (I-b), each symbol is as defined in the description.] 

Therapeutic agent for glaucoma

The present invention relates to arylamidrazone derivatives having an antagonistic action against S1Preceptors represented by the following formula (1) or a pharmaceutically acceptable salt thereof: 

[object Object]

The present invention relates to an N-substituted benzothiophenesulfonamide derivative or a pharmaceutically acceptable salt thereof and applications thereof. Furthermore, it provides an agent for preventing or treating cardiac or circulatory disease and so on caused by abnormal increase of production of angiotensin II or endothelin I based on chymase activity, or by activation of mast cell, and an agent for preventing adhesion after surgery, wherein the agent has a selective inhibitory action on chymase.

N-substituted benzothiophenesulfonamide derivatives

Growing community of inventors

Fukushima, Japan

Takeshi Hasegawa